The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Pharmaceutical cocrystals: from serendipity to design to application
Open accessAbstract
The field of pharmaceutical cocrystals has reached a tipping point, particularly because cocrystals can improve the physicochemical properties of drugs without compromising their therapeutic benefit. Accounts of cocrystal investigations in the literature started in earnest in 2003 and patent applications soon followed. The frequency of both has steadily accelerated, demonstrating an enhanced understanding of the design, characterisation, and manufacture of cocrystals and heightened interest from industry. Indeed, there were four new product approvals from 2014 to 2017 and more are in the pipeline. Here, we review all marketed drug products that are based upon pharmaceutical cocrystal drug substances, starting with the first recorded example, Beta-Chlor® in 1963, with a particular emphasis on their discovery, rationale for use, and market impact.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From Molecules to Crystal Engineering: Supramolecular Isomerism and Polymorphism in Network Solids
Moulton, B., & Zaworotko, M. J. (2001) · Chemical Reviews · doi:10.1021/cr9900432 · Cited by 6,395
Self-citationAmidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Supramolecular Synthons in Crystal Engineering—A New Organic Synthesis
Desiraju, G. R. (1995) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199523111 · Cited by 4,856
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Photodimerization in the solid state
Schmidt, G. M. J. (1971) · Pure and Applied Chemistry · doi:10.1351/pac197127040647 · Cited by 2,095
Crystal Engineering: A Holistic View
Desiraju, G. R. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700534 · Cited by 1,499
Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals
Babu, N. J., & Nangia, A. (2011) · Crystal Growth & Design · doi:10.1021/cg200492w · Cited by 1,004
Pharmaceutical cocrystals: along the path to improved medicines
Duggirala, N. K., Perry, M. L., Almarsson, Ö., & Zaworotko, M. J. (2016) · Chemical Communications · doi:10.1039/c5cc08216a · Cited by 928
Self-citationSolubility Advantage of Pharmaceutical Cocrystals
Good, D. J., & Rodríguez-Hornedo, N. (2009) · Crystal Growth & Design · doi:10.1021/cg801039j · Cited by 841
Pharmaceutical cocrystals and poorly soluble drugs
Thakuria, R., Delori, A., Jones, W., Lipert, M. P., Roy, L., & Rodríguez-Hornedo, N. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.10.043 · Cited by 614
Physical chemical analysis of percutaneous absorption process from creams and ointments.
Higuchi, T. (1960) · Medical Entomology and Zoology · Cited by 464
Weyna, D. R., Shattock, T., Vishweshwar, P., & Zaworotko, M. J. (2009) · Crystal Growth & Design · doi:10.1021/cg800936d · Cited by 445
Self-citationHigh throughput solubility measurement in drug discovery and development
Alsenz, J., & Kansy, M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.007 · Cited by 412
Berry, D. J., & Steed, J. W. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.003 · Cited by 406
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395
Guzmán, H. R., Tawa, M., Zhang, Z., Ratanabanangkoon, P., Shaw, P., Gardner, C. R., Chen, H., Moreau, J., Almarsson, Ö., & Remenar, J. F. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20906 · Cited by 381
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
Pan, S., Wu, X., Jiang, J., Gao, W., Wan, Y., Cheng, D., Han, D., Liu, J., Englund, N. P., Wang, Y., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1000307 · Cited by 325
Aakeröy, C. B., Forbes, S., & Desper, J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja907674c · Cited by 297
Solid form screening – A review
AALTONEN, J., ALLESO, M., MIRZA, S., KORADIA, V, GORDON, K., & RANTANEN, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.07.014 · Cited by 276
Caffeine therapy in preterm infants
Abdel‐Hady, H. (2015) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v4.i4.81 · Cited by 167
Regulation Tomorrow: What Happens When Technology Is Faster Than the Law?
Fenwick, M., Kaal, W. A., & Vermeulen, E. P. M. (2016) · SSRN Electronic Journal · doi:10.2139/ssrn.2834531 · Cited by 163
Imamura, M., Nakanishi, K., Suzuki, T., Ikegai, K., Shiraki, R., Ogiyama, T., Murakami, T., Kurosaki, E., Noda, A., Kobayashi, Y., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.03.051 · Cited by 139
Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics
Shan, N., Perry, M. L., Weyna, D. R., & Zaworotko, M. J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.942281 · Cited by 136
Self-citationCocrystal Eutectic Constants and Prediction of Solubility Behavior
Good, D. J., & Rodríguez‐Hornedo, N. (2010) · Crystal Growth & Design · doi:10.1021/cg901232h · Cited by 128
The a to Z of Pharmaceutical Cocrystals: A Decade of Fast-Moving New Science and Patents
Almarsson, Ö., Peterson, M. L., & Zaworotko, M. J. (2012) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.12.29 · Cited by 101
Self-citationContinuous manufacturing of co-crystals: challenges and prospects
Chavan, R. B., Thipparaboina, R., Yadav, B., & Shastri, N. R. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0479-7 · Cited by 71
Can pharmaceutical co-crystals provide an opportunity to modify the biological properties of drugs?
Dalpiaz, A., Pavan, B., & Ferretti, V. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.010 · Cited by 62
Maximising success in multidrug formulation development: A review
Kavanagh, O. N., Albadarin, A. B., Croker, D. M., Healy, A. M., & Walker, G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.024 · Cited by 45
Self-citationKish, T. D., & Corry, L. (2016) · PubMed · Cited by 23
Valsartan in Chronic Heart Failure
Forfar, J. C., & Munir, S. (2002) · New England Journal of Medicine · doi:10.1056/nejm200204113461516 · Cited by 19
Peikova, L., Manova, M. M., Georgieva, S., & Petrova, G. I. (2013) · Biotechnology & Biotechnological Equipment · doi:10.5504/bbeq.2013.0048 · Cited by 7
Cited by
Crystal Engineering of Pharmaceutical Cocrystals in the Discovery and Development of Improved Drugs
Bolla, G., Sarma, B., & Nangia, A. K. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00987 · Cited by 597
Structural Analysis of Molecular Materials Using the Pair Distribution Function
Terban, M. W., & Billinge, S. J. L. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00237 · Cited by 426
Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications
Guo, M., Sun, X., Chen, J., & Cai, T. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.030 · Cited by 386
Metadata
- Authors
- Kavanagh, O. N., Croker, D. M., Walker, G. M., & Zaworotko, M. J.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 24
- Issue
- 3
- Pages
- 796-804
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2902359770
- Cited by
- 323
- References
- 32
- FWCI
- 18.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.